TY - JOUR
T1 - Relationship of serum beta-synuclein with blood biomarkers and brain atrophy
AU - for the FTLD Consortium
AU - Oeckl, Patrick
AU - Anderl-Straub, Sarah
AU - Danek, Adrian
AU - Diehl-Schmid, Janine
AU - Fassbender, Klaus
AU - Fliessbach, Klaus
AU - Halbgebauer, Steffen
AU - Huppertz, Hans Jürgen
AU - Jahn, Holger
AU - Kassubek, Jan
AU - Kornhuber, Johannes
AU - Landwehrmeyer, Bernhard
AU - Lauer, Martin
AU - Prudlo, Johannes
AU - Schneider, Anja
AU - Schroeter, Matthias L.
AU - Steinacker, Petra
AU - Volk, Alexander E.
AU - Wagner, Matias
AU - Winkelmann, Juliane
AU - Wiltfang, Jens
AU - Ludolph, Albert C.
AU - Otto, Markus
N1 - Publisher Copyright:
© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2023/4
Y1 - 2023/4
N2 - Background: Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD). Methods: We provide a detailed comparison of serum beta-synuclein immunoprecipitation – mass spectrometry (IP-MS) with the established blood markers phosphorylated tau 181 (p-tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores. Results: Serum beta-synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta-synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p-tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy. Discussion: Serum beta-synuclein changes differ from those of NfL and p-tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta-synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations. Highlights: Blood beta-synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta-synuclein correlates with temporal brain atrophy in AD. Blood beta-synuclein correlates with cognitive impairment in AD. The pattern of blood beta-synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p-tau181) and neurofilament light (NfL).
AB - Background: Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD). Methods: We provide a detailed comparison of serum beta-synuclein immunoprecipitation – mass spectrometry (IP-MS) with the established blood markers phosphorylated tau 181 (p-tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores. Results: Serum beta-synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta-synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p-tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy. Discussion: Serum beta-synuclein changes differ from those of NfL and p-tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta-synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations. Highlights: Blood beta-synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta-synuclein correlates with temporal brain atrophy in AD. Blood beta-synuclein correlates with cognitive impairment in AD. The pattern of blood beta-synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p-tau181) and neurofilament light (NfL).
KW - Alzheimer's disease
KW - FTLD
KW - NfL
KW - beta-synuclein
KW - blood biomarker
KW - brain atrophy
KW - dementia
KW - frontotemporal lobar degeneration
KW - p-tau181
KW - synaptic degeneration
UR - http://www.scopus.com/inward/record.url?scp=85138439376&partnerID=8YFLogxK
U2 - 10.1002/alz.12790
DO - 10.1002/alz.12790
M3 - Article
C2 - 36129098
AN - SCOPUS:85138439376
SN - 1552-5260
VL - 19
SP - 1358
EP - 1371
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 4
ER -
